 Connection
Paul Bunn to Antineoplastic Agents
This is a "connection" page, showing publications Paul Bunn has written about Antineoplastic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
6.208 |
|
|
|
-
Hirsch FR, Sequist LV, Gore I, Mooradian M, Simon G, Croft EF, DeVincenzo D, Munley J, Stein D, Freivogel K, Sifakis F, Bunn PA. Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP). Cancer. 2018 06 01; 124(11):2407-2414.
Score: 0.287
-
Helfrich BA, Gao D, Bunn PA. Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy. Lung Cancer. 2018 04; 118:148-154.
Score: 0.284
-
Helfrich BA, Kim J, Gao D, Chan DC, Zhang Z, Tan AC, Bunn PA. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther. 2016 10; 15(10):2314-2322.
Score: 0.256
-
Hirsch FR, Bunn PA. Adjuvant TKIs in NSCLC: what can we learn from RADIANT? Nat Rev Clin Oncol. 2015 Dec; 12(12):689-90.
Score: 0.243
-
Bunn PA, Kim ES. Improving the Care of Patients With Stage IB Non-Small-Cell Lung Cancer: Role of Prognostic Signatures and Use of Cell Cycle Progression Biomarkers. Clin Lung Cancer. 2015 Jul; 16(4):245-51.
Score: 0.232
-
Hirsch FR, Bunn PA. A new generation of EGFR tyrosine-kinase inhibitors in NSCLC. Lancet Oncol. 2012 May; 13(5):442-3.
Score: 0.189
-
Hirsch FR, Mok TS, Borges V, Bunn PA. Molecularly targeted therapy: when to stop and when to continue? Lancet Oncol. 2010 Aug; 11(8):709-11.
Score: 0.169
-
Bunn PA, Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Oncologist. 2008; 13 Suppl 1:37-46.
Score: 0.141
-
Bunn PA. Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors? J Clin Oncol. 2007 Jun 20; 25(18):2504-5.
Score: 0.136
-
Weiss GJ, Zeng C, Kelly K, Tran ZV, Bunn PA. Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer. Clin Lung Cancer. 2007 Mar; 8(5):335-8.
Score: 0.133
-
Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Bar?n A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res. 2006 Dec 01; 12(23):7117-25.
Score: 0.131
-
Bunn PA. Can a single pill replace doublet chemotherapy in first-line therapy of advanced non-small cell lung cancer? Clin Cancer Res. 2006 Oct 15; 12(20 Pt 1):5919-20.
Score: 0.130
-
Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, Bar?n A, Franklin WA, Hirsch FR, Geraci MW, Bunn PA. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res. 2006 Aug; 4(8):521-8.
Score: 0.128
-
Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, Girard L, Gazdar AF, Minna JD, Bunn PA. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 2006 Jan 15; 66(2):944-50.
Score: 0.123
-
Hirsch FR, Bunn PA. Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations? J Clin Oncol. 2005 Dec 20; 23(36):9044-7.
Score: 0.122
-
Bunn PA. Platinums in lung cancer: sufficient or necessary? J Clin Oncol. 2005 May 01; 23(13):2882-3.
Score: 0.116
-
Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Bar?n AE, Zeng C, Johnson TK, Bunn PA. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):795-805.
Score: 0.115
-
Bunn PA. Early-stage NSCLC: the role of radiotherapy and systemic therapy. J Natl Compr Canc Netw. 2004 Sep; 2 Suppl 2:S31-40.
Score: 0.112
-
Bunn PA. The potential role of proteasome inhibitors in the treatment of lung cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4263s-4265s.
Score: 0.110
-
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 May 01; 22(9):1589-97.
Score: 0.109
-
Herbst RS, Bunn PA. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5813-24.
Score: 0.106
-
Raben D, Helfrich B, Ciardiello F, Bunn PA. Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know. Lung Cancer. 2003 Aug; 41 Suppl 1:S15-22.
Score: 0.104
-
Bunn PA, Shepherd FA, Sandler A, Le Chevalier T, Belani CP, Kosmidis PA, Scagliotti GV, Giaccone G. Ongoing and future trials of biologic therapies in lung cancer. Lung Cancer. 2003 Aug; 41 Suppl 1:S175-86.
Score: 0.104
-
Bunn PA, Lilenbaum R. Chemotherapy for elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):341-3.
Score: 0.101
-
Langston J, Patil T, Ross Camidge D, Bunn PA, Schenk EL, Pacheco JM, Jurica J, Waxweiler TV, Kavanagh BD, Rusthoven CG. CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer. Lung Cancer. 2023 04; 178:103-107.
Score: 0.100
-
Hirsch FR, Franklin WA, Bunn PA. What is the role of HER-2/neu and trastuzumab (Herceptin) in lung cancer? Lung Cancer. 2002 Jun; 36(3):263-4.
Score: 0.096
-
Hirsch FR, Franklin WA, Bunn PA. Expression of target molecules in lung cancer: challenge for a new treatment paradigm. Semin Oncol. 2002 Jun; 29(3 Suppl 9):2-8.
Score: 0.096
-
Chan DC, Gera L, Stewart JM, Helfrich B, Zhao TL, Feng WY, Chan KK, Covey JM, Bunn PA. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents. Clin Cancer Res. 2002 May; 8(5):1280-7.
Score: 0.095
-
Chan D, Gera L, Stewart J, Helfrich B, Verella-Garcia M, Johnson G, Baron A, Yang J, Puck T, Bunn P. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism. Proc Natl Acad Sci U S A. 2002 Apr 02; 99(7):4608-13.
Score: 0.095
-
Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):37-46.
Score: 0.094
-
Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA. HER2/neu expression in malignant lung tumors. Semin Oncol. 2002 Feb; 29(1 Suppl 4):51-8.
Score: 0.094
-
Bunn PA, Mault J, Kelly K. Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer: a time for reassessment? Chest. 2000 Apr; 117(4 Suppl 1):119S-122S.
Score: 0.082
-
Pisters KM, Ginsberg RJ, Giroux DJ, Putnam JB, Kris MG, Johnson DH, Roberts JR, Mault J, Crowley JJ, Bunn PA. Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg. 2000 Mar; 119(3):429-39.
Score: 0.082
-
Blumenthal GM, Bunn PA, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol. 2018 Dec; 13(12):1818-1831.
Score: 0.074
-
Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998 May; 4(5):1087-100.
Score: 0.072
-
Kelly K, Hazuka M, Pan Z, Murphy J, Caskey J, Leonard C, Bunn PA. A phase I study of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation in patients with regionally inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1998 Feb 01; 40(3):559-67.
Score: 0.071
-
Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res. 2018 03 01; 24(5):1038-1047.
Score: 0.070
-
Paz-Ares LG, Zimmermann A, Ciuleanu T, Bunn PA, Antonio BS, Denne J, Iturria N, John W, Scagliotti GV. Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer. 2017 02; 104:45-51.
Score: 0.066
-
Suda K, Bunn PA, Rivard CJ, Mitsudomi T, Hirsch FR. Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal?from the Bench. J Thorac Oncol. 2017 01; 12(1):27-35.
Score: 0.064
-
Hirsch FR, Suda K, Wiens J, Bunn PA. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016 Sep 03; 388(10048):1012-24.
Score: 0.064
-
Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol. 2014 Dec 01; 32(34):3824-30.
Score: 0.057
-
Weickhardt AJ, Doebele RC, Purcell WT, Bunn PA, Oton AB, Rothman MS, Wierman ME, Mok T, Popat S, Bauman J, Nieva J, Novello S, Ou SH, Camidge DR. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer. 2013 Jul 01; 119(13):2383-90.
Score: 0.051
-
Kemme DJ, Bunn PA. State of the art therapy of mycosis fungoides and S?zary syndrome. Oncology (Williston Park). 1992 Feb; 6(2):31-42; discussion 44, 47-8.
Score: 0.047
-
Hickinson DM, Marshall GB, Beran GJ, Varella-Garcia M, Mills EA, South MC, Cassidy AM, Acheson KL, McWalter G, McCormack RM, Bunn PA, French T, Graham A, Holloway BR, Hirsch FR, Speake G. Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib. Clin Transl Sci. 2009 Jun; 2(3):183-92.
Score: 0.039
-
Kelly K, Kittelson J, Franklin WA, Kennedy TC, Klein CE, Keith RL, Dempsey EC, Lewis M, Jackson MK, Hirsch FR, Bunn PA, Miller YE. A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer. Cancer Prev Res (Phila). 2009 May; 2(5):440-9.
Score: 0.039
-
Bunn PA. Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol. 1989 Apr; 16(2 Suppl 5):27-33.
Score: 0.038
-
Bunn PA. Novel therapies for non-small-cell lung cancer: a 2008 update. Clin Lung Cancer. 2009 Mar; 10 Suppl 1:S6.
Score: 0.038
-
Witta SE, Dziadziuszko R, Yoshida K, Hedman K, Varella-Garcia M, Bunn PA, Hirsch FR. ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC). Ann Oncol. 2009 Apr; 20(4):689-95.
Score: 0.038
-
Gera L, Chan DC, Simkeviciene V, Bunn PA, Stewart JM. N-(Fluorenyl-9-methoxycarbonyl)amino acid amide derivatives as a new class of anti-cancer agents. Adv Exp Med Biol. 2009; 611:465-6.
Score: 0.038
-
Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA, Haney J, Helfrich BA, Kato H, Hirsch FR, Franklin WA. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol. 2008 Jun; 19(6):1053-9.
Score: 0.036
-
Bunn PA, Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction. Oncologist. 2008; 13 Suppl 1:1-4.
Score: 0.035
-
Dziadziuszko R, Siemiatkowska A, Limon J, Rzyman W, Jassem J, Bunn PA, Varella-Garcia M, Hirsch FR. Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report. J Thorac Oncol. 2007 Jan; 2(1):91-2.
Score: 0.033
-
Dziadziuszko R, Holm B, Skov BG, Osterlind K, Sellers MV, Franklin WA, Bunn PA, Varella-Garcia M, Hirsch FR. Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. Ann Oncol. 2007 Mar; 18(3):447-52.
Score: 0.033
-
Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006 Nov 01; 24(31):5034-42.
Score: 0.033
-
Dziadziuszko R, Witta SE, Cappuzzo F, Park S, Tanaka K, Danenberg PV, Bar?n AE, Crino L, Franklin WA, Bunn PA, Varella-Garcia M, Danenberg KD, Hirsch FR. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res. 2006 May 15; 12(10):3078-84.
Score: 0.031
-
Cappuzzo F, Toschi L, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Cancellieri A, Magrini E, Bemis L, Franklin WA, Crino L, Bunn PA, Hirsch FR, Varella-Garcia M. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br J Cancer. 2005 Dec 12; 93(12):1334-40.
Score: 0.031
-
Stewart JM, Gera L, Chan DC, York EJ, Simkeviciene V, Bunn PA, Taraseviciene-Stewart L. Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists. Peptides. 2005 Aug; 26(8):1288-91.
Score: 0.030
-
Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA, Hirsch FR. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol. 2005 Aug 01; 23(22):5007-18.
Score: 0.030
-
Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA, Franklin WA, Crowley J, Gandara DR. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol. 2005 Oct 01; 23(28):6838-45.
Score: 0.030
-
Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA, Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005 May 04; 97(9):643-55.
Score: 0.029
-
Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignogna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, Ciardiello F, Bunn P. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Mol Cancer Ther. 2004 Aug; 3(8):977-83.
Score: 0.028
-
Lynch TJ, Adjei AA, Bunn PA, DuBois RN, Gandara DR, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, Schiller JH, Shapiro GI, Socinski MA, Hart CS. Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4199s-4204s.
Score: 0.028
-
Hirsch FR, Bunn PA, Johnson DH, Giaccone G, Rosell R. Lung cancer. Introduction. Lung Cancer. 2003 Aug; 41 Suppl 1:S1.
Score: 0.026
-
Stewart JM, Chan DC, Simkeviciene V, Bunn PA, Helfrich B, York EJ, Taraseviciene-Stewart L, Bironaite D, Gera L. Bradykinin antagonists as new drugs for prostate cancer. Int Immunopharmacol. 2002 Dec; 2(13-14):1781-6.
Score: 0.025
-
Stewart JM, Gera L, Chan DC, Bunn PA, York EJ, Simkeviciene V, Helfrich B. Bradykinin-related compounds as new drugs for cancer and inflammation. Can J Physiol Pharmacol. 2002 Apr; 80(4):275-80.
Score: 0.024
-
Bunn PA. [State-of-the art treatment of locally advanced and metastatic non-small cell lung cancer]. Anticancer Drugs. 2001 Jul; 12 Suppl 3:S3-8.
Score: 0.022
-
Agus DB, Bunn PA, Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol. 2000 Dec; 27(6 Suppl 11):53-63; discussion 92-100.
Score: 0.022
-
Bunn PA, Carney DN. Treatment of cutaneous T-cell lymphoma. J Dermatol Surg Oncol. 1980 May; 6(5):383-7.
Score: 0.021
-
Bunn PA, Soriano A, Johnson G, Heasley L. New therapeutic strategies for lung cancer: biology and molecular biology come of age. Chest. 2000 Apr; 117(4 Suppl 1):163S-168S.
Score: 0.021
-
Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA, Chou TC. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. 1999 Dec 15; 59(24):6178-84.
Score: 0.020
-
Stewart JM, Gera L, York EJ, Chan DC, Bunn P. Bradykinin antagonists: present progress and future prospects. Immunopharmacology. 1999 Sep; 43(2-3):155-61.
Score: 0.020
-
Bunn PA, Fischmann AB, Schechter GP, Kumar PP, Ihde DC, Cohen MH, Fossieck BE, Gazdar AF, Matthews MJ, Eddy JL, Minna JD. Combined modality therapy with electron-beam irradiation and systemic chemotherapy for cutaneous T-cell lymphomas. Cancer Treat Rep. 1979 Apr; 63(4):713-7.
Score: 0.019
-
Patil T, Smith DE, Bunn PA, Aisner DL, Le AT, Hancock M, Purcell WT, Bowles DW, Camidge DR, Doebele RC. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol. 2018 11; 13(11):1717-1726.
Score: 0.018
-
Kelly K, Bunn PA. Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer. 1998 May; 20(2):85-91.
Score: 0.018
-
Bunn PA. Rational therapy for cutaneous T-cell lymphomas in the 1990s. Fact or fancy? Arch Dermatol. 1995 May; 131(5):603-5.
Score: 0.015
-
Bunn PA. Letter: Should ineffective agents be used in combination chemotherapy? Cancer Chemother Rep. 1974 Mar-Apr; 58(2):127-8.
Score: 0.014
-
Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA, Pao W. Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res. 2013 May 01; 19(9):2584-91.
Score: 0.013
-
Mascaux C, Feser WJ, Lewis MT, Bar?n AE, Coldren CD, Merrick DT, Kennedy TC, Eckelberger JI, Rozeboom LM, Franklin WA, Minna JD, Bunn PA, Miller YE, Keith RL, Hirsch FR. Endobronchial miRNAs as biomarkers in lung cancer chemoprevention. Cancer Prev Res (Phila). 2013 Feb; 6(2):100-8.
Score: 0.012
-
Cas?s-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA, Chan DC, Tan AC, DeGregori J. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res. 2012 Aug 15; 72(16):4154-64.
Score: 0.012
-
Hazuka MB, Bunn PA. Controversies in the nonsurgical treatment of stage III non-small cell lung cancer. Am Rev Respir Dis. 1992 Apr; 145(4 Pt 1):967-77.
Score: 0.012
-
Einhorn LH, Bonomi P, Bunn PA, Camidge DR, Carbone DP, Choy H, Dubinett SM, Gandara DR, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, West HJ, Herbst RS. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. J Thorac Oncol. 2008 May; 3(5):545-55.
Score: 0.009
-
Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA, Raben D. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther. 2007 Jun; 6(6):1683-91.
Score: 0.008
-
Sunpaweravong P, Magree L, Rabinovitch R, Bunn P, Kelly K. A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer. Invest New Drugs. 2006 May; 24(3):213-21.
Score: 0.008
-
Batist G, Ihde DC, Zabell A, Lichter AS, Veach SR, Cohen MH, Carney DN, Bunn PA. Small-cell carcinoma of lung: reinduction therapy after late relapse. Ann Intern Med. 1983 Apr; 98(4):472-4.
Score: 0.006
-
Bradley EC, Schechter GP, Matthews MJ, Whang-Peng J, Cohen MH, Bunn PA, Ihde DC, Minna JD. Erythroleukemia and other hematologic complications of intensive therapy in long-term survivors of small cell lung cancer. Cancer. 1982 Jan 15; 49(2):221-3.
Score: 0.006
-
Earle MF, Fossieck BE, Cohen MH, Ihde DC, Bunn PA, Minna JD. Perirectal infections in patients with small cell lung cancer. JAMA. 1981 Nov 27; 246(21):2464-6.
Score: 0.006
-
Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma. 2001 Mar; 41(1-2):77-87.
Score: 0.005
-
Broder S, Bunn PA. Cutaneous T-cell lymphomas. Semin Oncol. 1980 Sep; 7(3):310-31.
Score: 0.005
-
Shackney SE, Bunn PA, Ford SS, Erickson B, Ross WE, Levine AS. A study of drug-induced kinetic perturbations in the marrow of a patient with neuroblastoma. Cancer. 1980 Mar 01; 45(5):882-92.
Score: 0.005
-
Cohen MH, Chretien PB, Ihde DC, Fossieck BE, Makuch R, Bunn PA, Johnston AV, Shackney SE, Matthews MJ, Lipson SD, Kenady DE, Minna JD. Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer. JAMA. 1979 Apr 27; 241(17):1813-5.
Score: 0.005
-
Cohen MH, Ihde DC, Bunn PA, Fossieck BE, Matthews MJ, Shackney SE, Johnston-Early A, Makuch R, Minna JD. Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Cancer Treat Rep. 1979 Feb; 63(2):163-70.
Score: 0.005
-
Bunn PA, Nugent JL, Matthews MJ. Central nervous system metastases in small cell bronchogenic carcinoma. Semin Oncol. 1978 Sep; 5(3):314-22.
Score: 0.005
-
Cohen MH, Bunn PA, Ihde DC, Fossieck BE, Minna JD. Chemotherapy rather than demeclocycline for inappropriate secretion of antidiuretic hormone. N Engl J Med. 1978 Jun 22; 298(25):1423-4.
Score: 0.005
-
Bunn PA, Cohen MH, Ihde DC, Fossieck BE, Matthews MJ, Minna JD. Advances in small cell bronchogenic carcinoma. Cancer Treat Rep. 1977 May-Jun; 61(3):333-42.
Score: 0.004
-
Funa K, Dawson N, Jewett PB, Agren H, Ruckdeschel JC, Bunn PA, Gazdar AF. Automated fluorescent analysis for drug-induced cytotoxicity assays. Cancer Treat Rep. 1986 Oct; 70(10):1147-51.
Score: 0.002
-
Bleehen NM, Bunn PA, Cox JD, Dombernowsky P, Fox RM, H?st H, Joss R, White JE, Wittes RE. Role of radiation therapy in small cell anaplastic carcinoma of the lung. Cancer Treat Rep. 1983 Jan; 67(1):11-9.
Score: 0.002
-
Carney DN, Marangos PJ, Ihde DC, Bunn PA, Cohen MH, Minna JD, Gazdar AF. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet. 1982 Mar 13; 1(8272):583-5.
Score: 0.001
-
Minna JD, Bunn PA, Carney DN, Cohen MH, Cuttita F, Fosieck BE, Gazdar AF, Ihde DC, Johnston-Early A, Matthews MJ, Makuch R, Oie H, Rosen S, Lichter A, Glatstein E. Experience of the National Cancer Institute (USA) in the treatment and biology of small cell lung cancer. Bull Cancer. 1982; 69(1):83-93.
Score: 0.001
-
Levenson RM, Sauerbrunn BJ, Ihde DC, Bunn PA, Cohen MH, Minna JD. Small cell lung cancer: radionuclide bone scans for assessment of tumor extent and response. AJR Am J Roentgenol. 1981 Jul; 137(1):31-5.
Score: 0.001
-
Huberman M, Fossieck BE, Bunn PA, Cohen MH, Ihde DC, Minna JD. Herpes zoster and small cell bronchogenic carcinoma. Am J Med. 1980 Feb; 68(2):214-8.
Score: 0.001
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|